

25. Furniss D, Harnden P, Ali N, et al. Prognostic factors for renal cell carcinoma. *Cancer Treatment Reviews*. 2008; 34(5): 407–26.
26. Kirkali Z, Lekili M. Renal cell carcinoma: new prognostic factors? *Current Opinion in Urology*. 2003; 13(6): 433–8.
27. Rivet J, Mourah S, Murata H, et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. *Cancer*. 2008; 112(2): 433–42.
28. Bensalah K, Rioux-Leclercq N, Vincendeau S, et al. Is tumour expression of VEGF associated with venous invasion and survival in pT3 renal cell carcinoma? *Progres En Urologie*. 2007; 17(2): 189–93.
29. Kluger HM, Siddiqui SF, Angeletti C, et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. *Laboratory Investigation*. 2008; 88(9): 962–72.
30. Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. *World Journal of Urology*. 2018; 36(12): 1943–52.
31. Hodorova I, Solar P, Mihalik J, et al. Investigation of tumour suppressor protein p53 in renal cell carcinoma patients. *Biomedical Papers-Olomouc*. 2014; 158(1): 44–9.
32. Gudowska-Sawczuk M, Kudelski J, Mroczko B. The Role of Chemokine Receptor CXCR3 and Its Ligands in Renal Cell Carcinoma. *International Journal of Molecular Sciences*. 2020; 21(22).
33. Bratu O, Mischianu D, Marcu D, et al. Renal tumor biomarkers (Review). *Experimental and Therapeutic Medicine*. 2021; 22(5).
34. Tschirdewahn S, Panic A, Pullen L, et al. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma. *International Journal of Cancer*. 2019; 145(2): 531–9.
35. Yang F, Song Y, Ge L, et al. Long non-coding RNAs as prognostic biomarkers in papillary renal cell carcinoma. *Oncology Letters*. 2019.
36. Felekakis K, Touvana E, Stefanou C, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. *Hippokratia*. 2010; 14(4): 236–40.
37. Slaby O, Jancovicova J, Lakomy R, et al. Expression of miRNA-106 b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. *Journal of Experimental & Clinical Cancer Research*. 2010; 29.
38. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. *Nucleic Acids Research*. 2008; 36: D154–D8.
39. Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. *Nature Reviews Cancer*. 2006; 6(4): 259–69.
40. Wang F, Zhang HX, Xu NH, et al. A novel hypoxia-induced miR-147a regulates cell proliferation through a positive feedback loop of stabilizing HIF-1. *Cancer Biology & Therapy*. 2016; 17(8): 790–8.
41. Iwamoto H, Kanda Y, Sejima T, et al. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. *International Journal of Oncology*. 2014; 44(1): 53–8.
42. Iwamoto H, Osaki M, Honda M, et al. miR-210 as a Biomarker in Renal Carcinoma. *Biomarkers in Kidney Disease*. 2016; 1–2: 895–910.
43. Lu J, Wei JH, Feng ZH, et al. miR-106 b-5p promotes renal cell carcinoma aggressiveness and stem-cell-like phenotype by activating Wnt/beta-catenin signalling. *Oncotarget*. 2017; 8(13): 21461–71.
44. Li YF, Chen DQ, Su ZM, et al. MicroRNA-106 b functions as an oncogene in renal cell carcinoma by affecting cell proliferation, migration and apoptosis. *Molecular Medicine Reports*. 2016; 13(2): 1420–6.
45. Papadopoulos EI, Petraki C, Gregorakis A, et al. Clinical evaluation of microRNA-145 expression in renal cell carcinoma: a promising molecular marker for discriminating and staging the clear cell histological subtype. *Biological Chemistry*. 2016; 397(6): 529–39.